Cleveland BioLabs News
InPlay: Cleveland Biolabs and Incuron announce US and European patent allowances for curaxins
May 14Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Curaxins
GlobeNewswire May 14BUFFALO, N.Y. -- Cleveland BioLabs, Inc. and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced the receipt of a Notice of Allowance from the U.S. Patent ...
Cleveland BioLabs' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha May 9Cleveland BioLabs' CEO Discusses Q1 2013 Results - Earnings Call Transcript
CORRECTION -- Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress
GlobeNewswire May 9BUFFALO, N.Y. -- In a release issued earlier today under the same headline by Cleveland BioLabs, Inc. , the years in the column headers in the Consolidated Balance Sheets table were incorrect. With the ...
Cleveland Biolabs, Inc. (CBLI) Posts Q1 Loss of 22c/Share
Street Insider May 9Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress
GlobeNewswire May 9BUFFALO, N.Y. -- Cleveland BioLabs, Inc. today reported financial results and development progress for the first quarter ended March 31, 2013.
Cleveland BioLabs Announces Appointment of Shareholder Representative to Board
GlobeNewswire May 8BUFFALO, N.Y. -- Cleveland BioLabs, Inc. today announced that its board of directors has appointed a shareholder representative, Randy S. Saluck, J.D., MBA as an independent director.
Isis Initiates ISIS-STAT3 Study - Analyst Blog
Zacks May 7Isis Pharma announced the initiation of a phase Ib/IIa study on ISIS-STAT3
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBLI | 1.63 | +0.07 | +4.49% | 73.08M |
